Pets Choice Limited have recently established a new Veterinary Division, with a ManSA license granted by the Veterinary Medicines Directorate (VMD). The license allows Pets Choice to develop a range of Cannabidiol (CBD) oral dosage formats capable of being prescribed under the cascade.
This latest diversification into unlicensed veterinary medicines will allow the company to focus on the immediate unmet needs of the veterinary sector, with a particular focus on emerging therapy areas such as CBD, for example.
“Veterinary professionals across the world increasingly prescribing CBD products to their patients for a variety of health conditions including osteoarthritis, epilepsy, pain management and a variety of other behavioural issues.” said Glesni Owen, head of veterinary sales.
“Research into the use of CBD is advancing daily which provides veterinary professionals with an increased knowledge base to help clients make informed decisions about treating their pets.”
Pets Choice have been working closely with veterinary professionals in the United States, where CBD therapy is far more widely prescribed, collating and sharing the latest supporting evidence and guidance for vets here in the UK to feel comfortable discussing it with their clients.
If you would like further information or to discuss your veterinary clinic’s requirements, please email in or call the Pets Choice office on 01934 831000.
“The use of CBD (Cannabidiol) therapy in veterinary medicine”, a webinar presented by Jeffrey Powers, DVM, is available online.